Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D). We offer end-to-end model generation services, from design to phenotype analysis, as well as comprehensive CRO services, including: disease model development, AAV discovery, viral vector manufacturing, and CAR-T/-NK cell construction.
Our specialized CRO platforms for drug discovery and preclinical research include ophthalmology, immuno-oncology, and neuroscience.
Cyagen has established collaborations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.